Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health (Nasdaq: GH) will participate in three investor conferences in May–June 2026, including fireside chats and a presentation.
Events: BofA Securities Healthcare Conference (May 12, 10:40 a.m. PT), William Blair Growth Stock Conference (June 2, 9:20 a.m. CT), and Jefferies Global Healthcare Conference (June 3, 11:05 a.m. ET). Live and archived webcasts will be available on the company website.
Guardant Health (Nasdaq: GH) will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Live audio will be available on the company’s Investors webpage and archived for replay after the event.
Guardant Health (Nasdaq: GH) said real-world evidence from its InfinityAI platform supported Japan approval of ENHERTU (trastuzumab deruxtecan) for previously treated HER2-positive advanced or recurrent solid tumors.
The MHLW approval was supported by clinical trial data plus supplemental RWE from InfinityAI and Guardant360, supplied in collaboration with Daiichi Sankyo.
Verana Health and Guardant Health (Nasdaq: GH) announced a March 24, 2026 partnership to combine Verana's curated, therapeutic-specific EHR datasets with Guardant's clinicogenomic testing data to accelerate oncology drug development and improve real-world treatment insights.
The merged Verana/COTA portfolio expands reach to >95 million patients, >20,000 clinicians, and accessible oncology patients to over 10 million.
Guardant Health (Nasdaq: GH) will present 28 abstracts, including 3 oral sessions, at AACR Annual Meeting, April 17-22, 2026 in San Diego. Key data include ~92% tissue-of-origin accuracy across >6,000 samples and expanded liquid biopsy actionability of 85% (metastatic breast) and 89% (advanced colorectal).
Presentations highlight methylation-based tumor typing, Guardant360 Liquid epigenomic features, Guardant Reveal MRD use to detect new primary cancers, and a tissue GIS for DNA repair deficiency to inform PARP inhibitor eligibility.
Guardant Health (Nasdaq: GH) launched its Shield™ multi-cancer detection (MCD) laboratory-developed blood test in Asia via a partnership with Manulife, with availability in Hong Kong, Singapore and the Philippines beginning April 2026 for eligible Manulife customers.
The methylation-based Shield MCD screens for 10 cancer types in individuals aged 45+ at typical average risk and has received FDA Breakthrough Device Designation in the United States based on NCI Vanguard study performance.
Guardant Health (Nasdaq: GH) released a Harris Poll showing 92% of Americans ages 45+ support blood-based colorectal cancer screening being covered with no co-pay similar to Medicare.
The survey reports Shield, an FDA-approved blood test, had 93% adherence in the first 100,000 tests and is covered by Medicare, VA Community Care, and TRICARE.
Guardant Health (Nasdaq: GH) announced that its Shield blood-based colorectal cancer screening test is now orderable through Quest Diagnostics' national test ordering and collection network.
Shield is the first blood test with full FDA approval as a primary CRC screening for average-risk adults 45+, available via Quest to nearly 650,000 clinician accounts, ~2,000 patient centers and ~6,000 in-office phlebotomists. Shield reported a 93% screening completion rate in the first 100,000 tests and is covered by Medicare, VA Community Care Network and TRICARE, with inclusion in updated NCCN CRC screening guidelines.
Guardant Health (Nasdaq: GH) launched Shield Across America on March 4, 2026, a coast-to-coast mobile screening tour delivering Shield, the first FDA-approved blood test for primary colorectal cancer screening, to over 100 communities with emphasis on rural areas.
The tour aims to raise screening rates—Shield recorded 93% adherence in its first 100,000 orders—and coincides with National Colorectal Cancer Awareness Month; Shield is covered by Medicare, VA Community Care, and TRICARE and is available by prescription.
Guardant Health (Nasdaq: GH) announced a partnership with actor Patrick Dempsey to raise awareness of colorectal cancer (CRC) screening and the FDA-approved Shield blood test during CRC Awareness Month (March 2026).
Key points: Shield is FDA-approved (2024) as a primary CRC screening option for adults 45+ at average risk, delivered via a routine blood draw, with results typically available within two weeks and real-world completion of 93% in the first 100,000 tests ordered. Shield was recently included in updated NCCN CRC screening guidelines.